BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of “Moderate Buy” by Analysts

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has received a consensus recommendation of “Moderate Buy” from the twenty-five research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and seventeen have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $90.0417.

A number of research analysts have issued reports on BMRN shares. Leerink Partners lowered shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and cut their price target for the company from $82.00 to $60.00 in a research note on Wednesday, December 3rd. Royal Bank Of Canada reissued a “sector perform” rating and issued a $66.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Truist Financial boosted their price target on BioMarin Pharmaceutical from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Finally, Wedbush restated an “outperform” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 28th.

BioMarin Pharmaceutical Stock Down 0.8%

Shares of BMRN stock opened at $56.54 on Friday. The stock’s fifty day moving average price is $56.51 and its 200 day moving average price is $55.96. BioMarin Pharmaceutical has a 1-year low of $50.76 and a 1-year high of $73.51. The company has a market cap of $10.86 billion, a price-to-earnings ratio of 21.26, a price-to-earnings-growth ratio of 0.62 and a beta of 0.27. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.10.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of the business. V Square Quantitative Management LLC purchased a new position in shares of BioMarin Pharmaceutical during the second quarter worth $25,000. Activest Wealth Management acquired a new stake in BioMarin Pharmaceutical during the 4th quarter worth about $26,000. Quent Capital LLC acquired a new stake in BioMarin Pharmaceutical during the 3rd quarter worth about $28,000. Smartleaf Asset Management LLC raised its stake in shares of BioMarin Pharmaceutical by 92.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 360 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter valued at about $40,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.